研究者業績
基本情報
- 所属
- 藤田医科大学 医学部 医学科 小児科学 教授
- 学位
- 臓器移植後のhuman herpesvirus 6(藤田保健衛生大学)
- J-GLOBAL ID
- 200901031230982717
- researchmap会員ID
- 5000044021
小児のウイルス感染症、特にヘルペスウイルスとロタウイルス感染を研究しています。
研究分野
1論文
466-
The Pediatric infectious disease journal 44(10) 937-941 2025年10月1日BACKGROUND: Kawasaki disease (KD) onset has been suggested to be associated with infections and various environmental factors. However, research on whether the delivery type plays a role in KD development is limited. This study investigated whether cesarean section (CS) or vaginal delivery (VD) is associated with KD onset using a large administrative claims database in Japan. METHOD: We conducted a case-control study using the JMDC Claims Database from January 2005 to December 2021. Data on children born via CS or VD and their mothers were collected. KD patients were identified from the source population, and controls without KD were randomly selected based on sex, age and registration time, each matched to 4 controls using a risk-set sampling technique. We analyzed the association between delivery type and KD onset using multivariate conditional logistic regression, defining KD as the primary outcome based on specific criteria. RESULTS: Case-control matching created 3363 pairs of cases (n = 3363) and controls (n = 13,363). The proportions of CS, maternal age, Charlson Comorbidity Index, presence of older siblings and low birth weight infants were significantly different between the cases and controls. In the multivariate analysis, KD onset was associated with CS [odds ratio (OR): 1.12; 95% confidence interval (CI): 1.02-1.24], the presence of older siblings (OR: 1.11; 95% CI: 1.02-1.21), lower birth weight (1001-2500 g) (OR: 1.22; 95% CI: 1.04-1.43) and antibiotic use (OR: 1.12; 95% CI: 1.02-1.24). CONCLUSIONS: The risk of developing KD may be influenced by the delivery type (CS or VD), the presence of older siblings, low birth weight and antibiotic use.
-
Journal of virology 99(9) e0105425 2025年9月23日Human herpesviruses 6A and 6B (HHV-6A/B) can integrate into the germline, resulting in inherited viral DNA-now proposed to be called "endogenous HHV-6A/B (eHHV-6A/B)." Present in 0.2-3% of humans, this integrated DNA is passed to offspring and may reactivate, posing health risks such as angina or lupus. To reduce confusion caused by varied terminology, researchers advocate using "eHHV-6A/B" for inherited forms and reserving "chromosomally integrated" for somatic integrations only.
-
Journal of medical virology 97(9) e70602 2025年9月The 12th International Conference on Human Herpesvirus (HHV)-6A, HHV-6B, and HHV-7 was held in Himeji, Japan, from March 25 to March 27, 2025. It attracted over 120 basic, translational, and clinical scientists from 17 countries. Important new information was presented regarding: studies of viral genes and proteins; mechanism of chromosomal integration of the viral genome; host cell interactions; inherited chromosomally integrated HHV-6A/B, also called endogenous HHV-6A/B); the role of the viruses in drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS); the role of the viruses as opportunistic pathogens in immunocompromised people; the role of the viruses in diseases of the central nervous system, particularly encephalopathy, post-COVID neurological conditions, complex febrile seizures, and synucleinopathies; and the possible role of the viruses in non-Hodgkin lymphoma and autoimmune diseases, including systemic lupus erythematosus. In this review, we summarize many of the oral presentations. The full text of the Conference Abstracts is available at: https://hhv-6foundation.org/wp-content/uploads/2025/06/Abstracts_FINAL-3.10.25.pdf.
-
The Journal of dermatology 2025年8月19日
-
Journal of the Pediatric Infectious Diseases Society 14(7) 2025年8月7日BACKGROUND: Pediatric acute hepatitis of unknown etiology (AHUE) has been reported globally since April 2022. The purpose of the present study was to investigate the impact of coronavirus disease 2019 (COVID-19) pandemic on the incidence of AHUE in Japan. METHODS: A nationwide survey of AHUE was conducted in 2510 pediatric hospitals by the Japan Pediatric Society. We retrospectively reviewed AHUE cases, defined by the World Health Organization's working case definition, and compared the incidence, clinical characteristics, and causative pathogens before the COVID-19 pandemic period (pre-pandemic, January 2017 to December 2019) and during the pandemic period (pandemic, January 2020 to June 2022). RESULTS: In total, 707 cases (450 pre-pandemic, 257 pandemic) were reported. The median age was 3 years (interquartile range (IQR): 1-9 years), and 43.8% were female. The number of AHUE cases decreased significantly in the pandemic period (102.8 cases/year) compared with the pre-pandemic period (150.0 cases/year). Investigations of pathogens causing AHUE demonstrated that the most common cause was unknown, accounting for 64% and 75% of cases in the pre-pandemic and pandemic periods, respectively. Among those whose pathogens were identified, the most common pathogens were Epstein-Barr virus (9.6%), cytomegalovirus (6.2%), and influenza (4.0%) in the pre-pandemic, and 7.0%, 3.5%, and 0.4%, respectively, in the pandemic period. SARS-CoV-2 and adenovirus were only 2.7% and 1.9%, respectively, in the pandemic period. CONCLUSIONS: The number of AHUE cases decreased during the COVID-19 pandemic compared with the pre-pandemic period, and no increase in adenovirus-associated disease or severe cases was observed in Japan.
MISC
342-
日本小児科学会雑誌 127(7) 1033-1038 2023年7月2022年より欧米から「原因不明の小児急性肝炎」について多くの報告があがるようになり、アデノウイルスや新型コロナウイルス感染症(COVID-19)流行との関連が疑われている。これまで本邦では小児の急性肝炎のサーベイランスが行われていないことから、今回、日本小児科学会会員が所属する全国の病院小児科責任者を対象に、2017年1月~2022年6月までの期間における同疾患の実態について質問紙調査を行い、947名より回答を得た。その結果、COVID-19流行前の報告数は2017年260名、2018年257名、2019年243名で、COVID-19流行中の報告数は2020年164名、2021年192名、2022年1~6月で113名と、COVID-19流行中の方が少ない傾向がみられた。COVID-19流行前は0歳および1~4歳群の症例数が他の年齢群と比較して多い傾向がみられたが、流行中はこれらの年齢群で減少が著明であった。地域別では、COVID-19流行前・流行後ともに、京都府・愛知県・福島県からの報告が多かった。
書籍等出版物
9講演・口頭発表等
17共同研究・競争的資金等の研究課題
29-
日本学術振興会 科学研究費助成事業 2024年4月 - 2027年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2022年4月 - 2025年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2021年4月 - 2024年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2021年4月 - 2024年3月
-
国立研究開発法人日本医療研究開発機構 新興・再興感染症に対する革新的医薬品等開発推進研究事業 2022年4月 - 2024年3月